Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Domenico Gabrielli

Showing results (61-70 of 288) with videos related to

Pageof 29
Sort By:
Frontiers in Cardiovascular Medicine|May 2, 2022
Clinical Impact and Prognostic Role of Triglyceride to High-Density Lipoprotein Cholesterol Ratio in Patients With Chronic Coronary Syndromes at Very High Risk: Insights From the START StudyLeonardo De Luca, Pier Luigi Temporelli, Furio Colivicchi, et al.
Giornale Italiano Di Cardiologia (2006)|July 20, 2019
[ANMCO Position paper: New perspectives on the role of n-3 polyunsaturated fatty acids in cardiovascular prevention]Furio Colivicchi, Fabio Vagnarelli, Pasquale Caldarola, et al.
International Journal of Cardiology|May 30, 2020
Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registryLeonardo De Luca, Marcello Arca, Pier Luigi Temporelli, et al.
Giornale Italiano Di Cardiologia (2006)|September 27, 2021
[ANMCO Position paper: Double, triple or quadruple therapy for heart failure with reduced ejection fraction. Current evidence and new strategies]Andrea Di Lenarda, Giuseppe Di Tano, Manlio Cipriani, et al.
Reviews in Cardiovascular Medicine|September 26, 2021
Current management and prognosis of patients with recurrent myocardial infarctionLeonardo De Luca, Luca Paolucci, Annunziata Nusca, et al.
International Journal of Cardiology|June 20, 2022
Potential pathophysiologic mechanisms underlying the inherent risk of cancer in patients with atherosclerotic cardiovascular diseaseStefania Angela Di Fusco, Cinzia Cianfrocca, Irma Bisceglia, et al.
Giornale Italiano Di Cardiologia (2006)|August 30, 2022
[Long COVID: nosographic aspects and clinical epidemiology]Maurizio G Abrignani, Alessandro Maloberti, Pier Luigi Temporelli, et al.
Giornale Italiano Di Cardiologia (2006)|May 25, 2023
[ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach]Stefania Angela Di Fusco, Lorenzo Castello, Gaetano Marino, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|June 20, 2020
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registryLeonardo De Luca, Dario Formigli, Jennifer Meessen, et al.
European Journal of Internal Medicine|May 6, 2022
Impact of eGFR rate on 1-year all-cause mortality in patients with stable coronary artery diseaseLeonardo De Luca, Francesca Cappadona, Pier Luigi Temporelli, et al.
Pageof 29

Showing results (61-70 of 288) with videos related to

Sort By:
Pageof 29
Frontiers in Cardiovascular Medicine|May 2, 2022
Clinical Impact and Prognostic Role of Triglyceride to High-Density Lipoprotein Cholesterol Ratio in Patients With Chronic Coronary Syndromes at Very High Risk: Insights From the START StudyLeonardo De Luca, Pier Luigi Temporelli, Furio Colivicchi, et al.
Giornale Italiano Di Cardiologia (2006)|July 20, 2019
[ANMCO Position paper: New perspectives on the role of n-3 polyunsaturated fatty acids in cardiovascular prevention]Furio Colivicchi, Fabio Vagnarelli, Pasquale Caldarola, et al.
International Journal of Cardiology|May 30, 2020
Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: Insights from the START registryLeonardo De Luca, Marcello Arca, Pier Luigi Temporelli, et al.
Giornale Italiano Di Cardiologia (2006)|September 27, 2021
[ANMCO Position paper: Double, triple or quadruple therapy for heart failure with reduced ejection fraction. Current evidence and new strategies]Andrea Di Lenarda, Giuseppe Di Tano, Manlio Cipriani, et al.
Reviews in Cardiovascular Medicine|September 26, 2021
Current management and prognosis of patients with recurrent myocardial infarctionLeonardo De Luca, Luca Paolucci, Annunziata Nusca, et al.
International Journal of Cardiology|June 20, 2022
Potential pathophysiologic mechanisms underlying the inherent risk of cancer in patients with atherosclerotic cardiovascular diseaseStefania Angela Di Fusco, Cinzia Cianfrocca, Irma Bisceglia, et al.
Giornale Italiano Di Cardiologia (2006)|August 30, 2022
[Long COVID: nosographic aspects and clinical epidemiology]Maurizio G Abrignani, Alessandro Maloberti, Pier Luigi Temporelli, et al.
Giornale Italiano Di Cardiologia (2006)|May 25, 2023
[ANMCO statement: Uric acid and cardiovascular disease: evidence and therapeutic approach]Stefania Angela Di Fusco, Lorenzo Castello, Gaetano Marino, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|June 20, 2020
COMPASS criteria applied to a contemporary cohort of unselected patients with stable coronary artery diseases: insights from the START registryLeonardo De Luca, Dario Formigli, Jennifer Meessen, et al.
European Journal of Internal Medicine|May 6, 2022
Impact of eGFR rate on 1-year all-cause mortality in patients with stable coronary artery diseaseLeonardo De Luca, Francesca Cappadona, Pier Luigi Temporelli, et al.
Pageof 29